Edwards Lifesciences Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Edwards Lifesciences yıllık ortalama 11.3% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 12% annual. Gelirler growing yılda ortalama 7.8% oranında artmaktadır. Edwards Lifesciences'in özkaynak karlılığı 16.3% ve net marjı 24.8%'dir.
Anahtar bilgiler
11.3%
Kazanç büyüme oranı
12.0%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | 8.9% |
| Gelir büyüme oranı | 7.8% |
| Özkaynak getirisi | 16.3% |
| Net Marj | 24.8% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Edwards Lifesciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 6,315 | 1,567 | 1,955 | 1,133 |
| 30 Jun 24 | 6,204 | 1,540 | 1,915 | 1,122 |
| 31 Mar 24 | 6,114 | 1,428 | 1,874 | 1,095 |
| 31 Dec 23 | 6,005 | 1,402 | 1,823 | 1,072 |
| 30 Sep 23 | 5,092 | 1,288 | 1,576 | 953 |
| 30 Jun 23 | 5,168 | 1,296 | 1,571 | 944 |
| 31 Mar 23 | 5,279 | 1,451 | 1,578 | 951 |
| 31 Dec 22 | 5,382 | 1,522 | 1,567 | 945 |
| 30 Sep 22 | 5,364 | 1,459 | 1,581 | 946 |
| 30 Jun 22 | 5,355 | 1,455 | 1,568 | 950 |
| 31 Mar 22 | 5,357 | 1,539 | 1,534 | 925 |
| 31 Dec 21 | 5,233 | 1,503 | 1,494 | 903 |
| 30 Sep 21 | 5,095 | 1,477 | 1,409 | 866 |
| 30 Jun 21 | 4,925 | 1,462 | 1,351 | 824 |
| 31 Mar 21 | 4,474 | 851 | 1,252 | 780 |
| 31 Dec 20 | 4,386 | 823 | 1,229 | 761 |
| 30 Sep 20 | 4,369 | 794 | 1,235 | 759 |
| 30 Jun 20 | 4,322 | 744 | 1,234 | 759 |
| 31 Mar 20 | 4,484 | 1,108 | 1,268 | 769 |
| 31 Dec 19 | 4,348 | 1,047 | 1,242 | 753 |
| 30 Sep 19 | 4,152 | 774 | 1,182 | 722 |
| 30 Jun 19 | 3,964 | 725 | 1,146 | 688 |
| 31 Mar 19 | 3,821 | 765 | 1,113 | 650 |
| 31 Dec 18 | 3,723 | 722 | 1,088 | 622 |
| 30 Sep 18 | 3,634 | 712 | 1,080 | 606 |
| 30 Jun 18 | 3,549 | 657 | 1,055 | 587 |
| 31 Mar 18 | 3,447 | 560 | 1,023 | 567 |
| 31 Dec 17 | 3,435 | 584 | 984 | 553 |
| 30 Sep 17 | 3,315 | 745 | 948 | 521 |
| 30 Jun 17 | 3,232 | 716 | 933 | 491 |
| 31 Mar 17 | 3,150 | 657 | 918 | 469 |
| 31 Dec 16 | 2,964 | 570 | 905 | 442 |
| 30 Sep 16 | 2,867 | 552 | 892 | 426 |
| 30 Jun 16 | 2,743 | 528 | 875 | 414 |
| 31 Mar 16 | 2,601 | 515 | 860 | 399 |
| 31 Dec 15 | 2,494 | 495 | 851 | 383 |
| 30 Sep 15 | 2,441 | 463 | 852 | 369 |
| 30 Jun 15 | 2,433 | 440 | 862 | 356 |
| 31 Mar 15 | 2,391 | 874 | 863 | 347 |
| 31 Dec 14 | 2,323 | 811 | 858 | 347 |
| 30 Sep 14 | 2,241 | 777 | 822 | 341 |
| 30 Jun 14 | 2,129 | 759 | 777 | 338 |
| 31 Mar 14 | 2,071 | 306 | 748 | 329 |
| 31 Dec 13 | 2,046 | 389 | 733 | 323 |
Kaliteli Kazançlar: EW yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: EW 'nin mevcut net kar marjları (24.8%) geçen yılın (25.3%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: EW şirketinin kazancı son 5 yılda yılda 11.3% oranında arttı.
Büyüme Hızlandırma: EW 'un son bir yıldaki kazanç büyümesi ( 21.7% ) 5 yıllık ortalamasını (yıllık 11.3% ) aşıyor.
Kazançlar vs. Sektör: EW geçen yılki kazanç büyümesi ( 21.7% ) Medical Equipment sektörünün 10.4% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: EW 'nin Özsermaye Getirisi ( 16.3% ) düşük olarak değerlendiriliyor.